Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy

被引：10
|
作者：
Crews, Kristine R. [1 ]
Caudle, Kelly E. [1 ]
Dunnenberger, Henry M. [2 ]
Sadhasivam, Senthilkumar [3 ,4 ]
Skaar, Todd C. [5 ]
机构：
[1] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA
[2] NorthShore Univ Hlth Syst, Ctr Mol Med, Evanston, IL USA
[3] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA
[4] Cincinnati Childrens Hosp Med Ctr, Dept Anesthesia, Cincinnati, OH USA
[5] Indiana Univ Sch Med, Div Clin Pharmacol, Dept Med, Indianapolis, IN 46202 USA
来源：
CLINICAL CHEMISTRY | 2015年 / 61卷 / 05期
关键词：
PHARMACOGENETICS; IMPLEMENTATION;
D O I：
10.1373/clinchem.2014.237412
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：775 / 776
页数：2
相关论文
共 50 条
  • [31] Venlafaxine serum levels and CYP2D6 genotype
    Veefkind, AH
    Hafmans, PMJ
    Hoencamp, E
    [J]. THERAPEUTIC DRUG MONITORING, 2000, 22 (02) : 202 - 208
  • [32] CYP2D6 GENOTYPE DETERMINATION IN THE DANISH POPULATION
    BROSEN, K
    NIELSEN, PN
    BRUSGAARD, K
    GRAM, LF
    SKJODT, K
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 47 (03) : 221 - 225
  • [33] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
    Hicks, J. K.
    Bishop, J. R.
    Sangkuhl, K.
    Mueller, D. J.
    Ji, Y.
    Leckband, S. G.
    Leeder, J. S.
    Graham, R. L.
    Chiulli, D. L.
    LLerena, A.
    Skaar, T. C.
    Scott, S. A.
    Stingl, J. C.
    Klein, T. E.
    Caudle, K. E.
    Gaedigk, A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 98 (02) : 127 - 134
  • [34] Functional phenotyping of the CYP2D6 probe drug codeine in the horse
    Gretler, S. R.
    Finno, C. J.
    Kass, P. H.
    Knych, H. K.
    [J]. BMC VETERINARY RESEARCH, 2021, 17 (01)
  • [35] Functional phenotyping of the CYP2D6 probe drug codeine in the horse
    S. R. Gretler
    C. J. Finno
    P. H. Kass
    H. K. Knych
    [J]. BMC Veterinary Research, 17
  • [36] Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer
    Susce, Margaret T.
    Murray-Carmichael, Elaina
    de Leon, Jose
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2006, 30 (07): : 1356 - 1358
  • [37] Quantitative assessment of the effect of CYP2D6 genotype on tamoxifen metabolism: A model for CYP2D6 genotype-phenotype studies.
    Borges, S
    Desta, Z
    Jin, Y
    Li, L
    Skaar, TC
    Flockhart, DA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (02) : P34 - P34
  • [38] Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype
    Mikus, G
    Trausch, B
    Rodewald, C
    Hofmann, U
    Richter, K
    Gramatte, T
    Eichelbaum, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (04) : 459 - 466
  • [39] Codeine abuse liability is modified by CYP2D6 inhibition.
    Romach, MK
    Kathiramalainathan, K
    Kaplan, HL
    Busto, UE
    Tyndale, RF
    Sellers, EM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PI107 - PI107
  • [40] Interaction between CYP2D6 inhibitor antidepressants and codeine: is this relevant?
    Cazet, Lucie
    Bulteau, Samuel
    Evin, Adrien
    Spiers, Andrew
    Caillet, Pascal
    Kuhn, Emmanuelle
    Pivette, Jacques
    Chaslerie, Anicet
    Jolliet, Pascale
    Victorri-Vigneau, Caroline
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (08) : 879 - 886
12345